Large, randomized trial shows integrative approach relieves common side effect of estrogen-suppressing drug
Dec. 7, 2017
| By Diane Mapes / Fred Hutch News Service
Results from a large multicenter trial released Thursday at the San Antonio Breast Cancer Symposium offer good news to early stage breast cancer patients dealing with painful side effects from powerful estrogen-squelching drugs known as aromatase inhibitors.
Li study confirms his earlier finding that associates long-term tamoxifen use with more than four-fold increased risk of aggressive, difficult to treat type of contralateral breast cancer
Aug. 26, 2009
| By Kristen Woodward
Findings by Dr. Christopher Li, and colleagues at the Fred Hutchinson Cancer Research Center indicate that while long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor.
Linden and colleagues find PET scans can provide accurate, early assessment of response to breast-cancer therapy
June 1, 2009
| By Dean Forbes
Dr. Hannah Linden of the Seattle Cancer Care Alliance and colleagues discovered the response of patient's with estrogen receptor positive breast cancer to standard aromatase-inhibitor therapy can be measured by noninvasive imaging with similar results to invasive needle sampling.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.